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Matriptase is highly upregulated in chronic lymphocytic leukemia and promotes cancer cell invasion Leukemia (2013) 27, 1191-1194; doi:10.1038/leu.2012.289
Matriptase, also called MT-SP1 or epithin, is a type-II transmembrane serine protease expressed on the surface of the normal epithelium.
1,2 The enzyme is required for epidermal differentiation and barrier function in the skin. Low levels of matriptase mRNA also were detected in human blood cells including monocytes and B lymphocytes, 3 but the biological significance of such expression is unclear. In monocytes, matriptase may be involved in initiating plasminogen activation. 3 Studies indicate that matriptase may have an important role in cancer. Matriptase overexpression has been reported in many human solid tumors, including prostate, breast, ovarian, kidney and lung cancers. 4, 5 In mice, transgenic matriptase expression in keratinocytes causes skin carcinoma. 6 The molecular mechanism under which matriptase may participate in cancer is not fully understood. Matriptase has been shown to activate pro-urokinase, prostasin, protease-activated receptor-2, pro-hepatocyte growth factor, pro-macrophage stimulating protein-1, platelet-derived growth factor, vascular endothelial growth factor receptor 2 and Tie2 receptor. 2, 4, [7] [8] [9] It is Accepted article preview online 9 October 2012; advance online publication, 26 October 2012
Letters to the Editor possible that these matriptase activities may promote cancer growth and invasion.
In this study, we tested the hypothesis that matripase may also participate in hematological cancers. By reverse transcriptase PCR (RT-PCR), we screened matriptase mRNA expression in hematological cancer cell lines and bone marrow cells from leukemia patients. Matriptase mRNA was detected in B-cell-derived Namalwa and Raji cells, but not in T-cell-derived (Hs 505.T, MOLT4, CCRF-CEM, Jurkat), chronic myeloid leukemia (CML)-derived (KU-812, MEG-01, K562) or acute myeloid leukemia (AML)-derived (U937, HEL, SH-2, SHI-1, THP-1, NB4) cells (Figure 1a) . A similar matriptase protein expression pattern in these cell lines was confirmed by western blotting (Figure 1b) , suggesting that matriptase may be upregulated in B-cell-derived cancers.
We then examined matriptase expression in bone marrow samples from 223 patients with different types of leukemia, including chronic lymphocytic leukemia (CLL) (n ¼ 81), acute lymphocytic leukemia (ALL) (n ¼ 74), AML (n ¼ 56) and CML (n ¼ 12). The study was approved by the ethics committee of Soochow University and all patients and normal controls (n ¼ 10) gave written informed consent. By RT-PCR, matriptase mRNA was detected in the majority of CLL samples (72/74, 97.3%), whereas most ALL, AML and CML samples were negative or weakly positive ( Figure 1c ). Similar results were found by western blotting, which detected matriptase protein in most CLL samples (79/81, 97.5%) but few samples of ALL (2/74, 2.7%) and AML (2/56, 3.6%) and none in CML (n ¼ 12) or normal peripheral blood (NPB) samples (n ¼ 10). Representative western blots (Figure 1d ) and quantitative analysis of selected western blots (Figure 1e ) are shown. Similar results also were found by quantitative PCR (qPCR), which showed 420-fold increases of matriptase mRNA expression in CLL samples compared with normal controls or other types of leukemia (Supplementary Figure 1) .
Matriptase is a transmembrane protein. 1 By immunostaining under non-permeable conditions, strong matriptase staining was detected on the surface of Namalwa and CLL cells but not NPB cells (Figure 1f) . A similar staining pattern was found with CD19, an established B-cell surface marker (Figure 1f ). In contrast, positive staining for CD3, a T-cell surface marker, was detected in NPB cells but not Namalwa and CLL cells (Supplementary Figure 2) . We confirmed matriptase cell surface expression by flow cytometry, which showed that 490% of Namalwa and CLL cells were matriptase positive, whereas only B1% NPB cells were matriptase positive (Figure 1g ). Similar results were found for CD19 cell surface expression (Figure 1g; Supplementary Figure 3) . These data indicate that matriptase is present on the CLL cell surface and may serve as a new cell surface marker for these leukemia cells. 
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The activity of matriptase is controlled by its cognate inhibitors, hepatocyte growth factor activator inhibitor (HAI)-1 and -2.
1,4,10
Uncontrolled matriptase activity has been implicated in cancer development and progression. By qPCR, we did not detect HAI-1 and HAI-2 mRNA upregulation in bone marrow cells from CLL patients (Supplementary Figure 4) . Instead, HAI-1 and HAI-2 mRNA upregulation was found in both B-and T-ALL cells, which were mostly matriptase negative (Supplementary Figure 4) . The data indicated that, unlike in many solid tumors, 11, 12 matriptase expression in CLL was not coupled with HAI-1 or HAI-2 expression, suggesting that increased matriptase activity may not be inhibited in CLL cells.
To examine the potential role of matriptase in cancer invasion, we used small hairpin (sh) RNA to silence matriptase expression in Namalwa cells. By qPCR and western blotting, matriptase mRNA and protein levels were decreased 490% in cells transduced with matripase-specific shRNA (siM) compared with that in cells transduced with a non-silencing shRNA control (siC) (Figures 2a and b) . In a transwell assay, cell invasion across matrigels was reduced by 89.1±5.9% in siM-transduced cells compared with that in control cells (Figure 2c) . In these cells, inhibition of matriptase expression did not appear to alter cell proliferation, as measured by a colorimetric assay (Figure 2d) .
We next examined the effect of a recombinant HAI-1 fragment containing Kunitz domain 1 (HAI-1-KD1), 13 which inhibits matriptase, on cancer cell invasion. HAI-1-KD1, but not control Kunitz-type soybean trypsin inhibitor, dose dependently inhibited Namalwa and Raji cells and bone marrow cells from CLL patients in matrigel invasion (Figures 2e, h and i) . Under these conditions, HAI-1-KD1 did not inhibit Namalwa, Raji or CLL cell proliferation or transwell migration in the absence of matrigels (Figures 2f and g ) (Supplementary Figures 5A and B) . In another experiment, HAI-1-KD1 did not inhibit matriptase-negative bone marrow cells from CML patients in matrigel invasion (Figure 2j ) or migration in the absence of matrigels (Supplementary Figure 5C) . In summary, we report for the first time that matriptase is highly expressed in CLL cells. As matriptase is also expressed in Namalwa and Raji cells (Figure 1 ), which are of Burkitt lymphoma origin, matriptase is probably expressed in other B-cell non-Hodgkin lymphomas. A preliminary study indeed detected matriptase expression in some patient samples of follicular lymphoma, marginal zone lymphoma and diffuse large B-cell lymphoma (data not shown), supporting that matriptase may be expressed in B-cell-derived malignancies. Interestingly, matriptase expression was not observed in AML, CML, T-ALL and B-ALL cells (Figure 1 and Supplementary Figure 1) . Thus, among leukemia cells, matriptase appeared to be expressed mostly in CLL cells, suggesting that matriptase may be used as a new cell surface marker for CLL.
Proteolytic enzymes are known to have important roles in cancers. 14, 15 We showed that inhibition of matriptase by either shRNA silencing or a recombinant matriptase inhibitor blocked Namalwa and Raji cells and patient CLL cells in matrigel invasion (Figure 2) . The results indicate that matriptase may contribute to the invasiveness of these B-cell-derived cancer cells, either directly by degrading matrix proteins or indirectly by activating growth factors or other unknown mechanisms. Our findings suggest that matriptase inhibition may be tested as a new therapeutic strategy to prevent CLL cell invasion and metastasis.
